Louisville, KY, United States
Louisville, KY, United States

Time filter

Source Type

Patent
SureGene | Date: 2015-05-04

This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ), and methods of use thereof.


Patent
SureGene | Date: 2013-03-20

This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ) and methods of use thereof. In particular, in vitro methods of predicting a human subjects likely response to treatment with risperidone, quetiapine, perphenazine or ziprasidone, of selecting a treatment for schizophrenia comprising administration of risperidone, quetiapine, perphenazine or ziprasidone, comprising detecting a haplotype comprising one or more polymorphic markers in DGKB or markers in linkage desiquilbrium (LD) therewith, are provided.


Patent
SureGene | Date: 2013-04-17

This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ), and methods of use thereof. In particular, in vitro methods of predicting a human subjects likely response to treatment with olanzapine, risperidone, quetiapine, or perphenazine, or of selecting a treatment for schizophrenia comprising administration of olanzapine, risperidone, quetiapine, or perphenazine, comprising detecting a haplotype comprising one or more polymorphic markers in ANK3 or markers in linkage disequilibrium (LD) therewith, are provided.


Patent
SureGene | Date: 2013-04-17

This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ), and methods of use thereof. In particular, in vitro methods of predicting a human subjects likely response to treatment with olanzapine, risperidone, quetiapine, perphenazine, or ziprasidone, or of selecting a treatment for schizophrenia comprising administration of olanzapine, risperidone, quetiapine, perphenazine, or ziprasidone, comprising detecting a haplotype comprising one or more polymorphic markers in UNC13C or markers in linkage disequilibrium (LD) therewith, are provided.


Patent
SureGene | Date: 2014-10-17

This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ) and methods of use thereof.


This document provides methods and materials related to genetic markers for predicting response to a treatment for schizophrenia (SZ). For example, methods for using such genetic markers to select optimal treatments are provided.


This document provides methods and materials related to genetic markers for predicting response to a treatment for schizophrenia (SZ). For example, methods for using such genetic markers to select optimal treatments are provided.


Patent
SureGene | Date: 2013-04-17

This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ), and methods of use thereof. In particular, in vitro methods of predicting a human subjects likely response to treatment with olanzapine, risperidone, quetiapine, or perphenazine, or of selecting a treatment for schizophrenia comprising administration of olanzapine, risperidone, quetiapine, or perphenazine, comprising detecting a haplotype comprising one or more polymorphic markers in SLCO3A1 or markers in linkage disequilibrium (LD) therewith, are provided.


Patent
SureGene | Date: 2013-04-17

This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ), and methods of use thereof. In particular, in vitro methods of predicting a human subjects likely response to treatment with olanzapine, risperidone, or ziprasidone, or of selecting a treatment for schizophrenia comprising administration of olanzapine, risperidone, or ziprasidone, comprising detecting a haplotype comprising one or more polymorphic markers in DNM3 or markers in linkage disequilibrium (LD) therewith, are provided.


Patent
SureGene | Date: 2014-06-10

Provided herein are genetic markers for predicting response to antipsychotic treatment. Identification of the disclosed SNPs can be used to predict response to antipsychotic drugs in patients suffering from schizophrenia.

Loading SureGene collaborators
Loading SureGene collaborators